NewsRoom Articles - Page 193 of 222

WednesdayDec 02, 2020 11:00 am

Researchers Find That Hypertension Increases Brain Damage Risk with Age

A research study conducted by Centre for Prevention of Stroke and Dementia clinical research fellow Dr. Karolina Wartolowska investigated the presence of white matter hyperintensities in the brain. These hyperintensities usually highlight small blood vessels that may be damaged and that manifest on MRI scans as bright regions. This damage is said to increase with blood pressure and age; the damage is linked to a decrease in cognitive function and an increased risk of depression, physical disabilities, dementia and stroke. The study involved 37,041 individuals enrolled in the UK Biobank. A huge chunk of the participants was recruited from the…

TuesdayDec 01, 2020 2:37 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Advances Brain Cancer Drug Candidate and Sponsors Annual SNO Conference

Biotechnology developer CNS Pharmaceuticals is preparing, with its partner WPD Pharmaceuticals, a global set of Phase 2 trials for its drug candidate Berubicin, which has shown promise in combating the effectively fatal glioblastoma multiforme (“GBM”) brain cancer Since another company conducted Phase 1 safety trials for Berubicin 14 years ago, one patient has survived cancer-free while two others saw reductions in tumor size of up to 80 percent The Phase 2 trials will build on the Phase 1 results, conducting targeted testing that offers side-by-side comparison between Berubicin and chemotherapy drug lomustine in real time beginning next year The company…

TuesdayDec 01, 2020 12:00 pm

Researchers Create Portable, Low-Cost MRI Scanner

If you’ve ever had to get a scan to assess for head trauma, then you probably had an MRI. The immobile and costly procedure is also used to detect brain cancer. To help make this diagnostic option more accessible, a group of scientists led by researchers from the Massachusetts General Hospital has created a portable, compact, low-cost MRI scanner. This scanner can be located in a doctor’s office or small clinics or installed in an ambulance. The portability of this power head only scanner also allows it to be wheeled into the ward or a patient’s room. This innovation was…

MondayNov 30, 2020 2:47 pm

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Preclinical Data for Potential Anxiety Treatment

VTGN CEO “even more excited about PH94B's potential to change lives without the risky side effects and safety concerns of benzos” Study results suggest PH94B's mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or abuse liability Company making significant progress in preparing PH94B for launch of pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder VistaGen Therapeutics (NASDAQ: VTGN) has reported new preclinical findings differentiating the mechanism of action of PH94B from that of benzodiazepines (https://ibn.fm/Al4ur). PH94B is an intranasal neuroactive steroid VistaGen is preparing for Phase 3 development…

MondayNov 30, 2020 11:00 am

Psychologist Explains Reason Behind Reckless Behavior Amid Worsening Pandemic

In the last month, COVID-19 cases have increased significantly in New Jersey and Pennsylvania. The recent numbers top the figures recorded during the first wave of the coronavirus when the pandemic first hit. The rising numbers isn’t the most puzzling factor about this; more puzzling may be the fact that, despite the rising cases, people continue to make plans to meet up with family and friends during the upcoming Thanksgiving holiday, instead of social distancing. To help contain the contagion, officials in Philadelphia introduced restrictions last week that limited the number of people in outdoor gatherings and closed museums, gyms…

WednesdayNov 25, 2020 11:00 am

Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Sells 15 Streamway(R) Systems in Q3 2020 as COVID-era Drives Need for Sanitation Systems

Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed into landfills POAI’s Skyline Medical sells 8 Streamway(R) Systems to large university hospital in Virginia, 15 sold halfway into Q3 2020 In the age of COVID-19, the need for sanitation and safety during hospital procedures has reached an all-time high. Health professionals have reported an inhibited level of performance due to a lack of protection, comfort, and increased fatigue during surgery (https://ibn.fm/87UEr). Sanitary disposal systems,…

WednesdayNov 25, 2020 11:00 am

Microorganisms Found in Child’s Bed Dust May Boost Their Health

In collaboration with the Gentofte Hospital and the Danish Pediatric Asthma Center, University of Copenhagen researchers from the Department of Biology have discovered a connection between children’s bacteria and the microorganisms that exist in the beds of children in an extensive study. This link implies that the microorganisms may decrease the risk of a child developing autoimmune diseases, allergies and asthma as they grow. While these microorganisms are invisible to the naked eye, they exist in multitudes in a child’s bed, influencing the development of microorganisms in children’s bodies. Ultimately, this impacts how resistant children become to different diseases. To…

WednesdayNov 25, 2020 10:45 am

AzurRx BioPharma Inc. (NASDAQ: AZRX) Planning to Test Immediate Release MS1819 Capsules in Cystic Fibrosis Study

The company plans to add another study arm to its ongoing Phase 2b OPTION 2 clinical study which currently tests delayed release capsules If it receives FDA approval, AzurRx would be able to identify the optimal delivery method for its drug candidate MS1819 without significant extra costs or delays Enrollment in this arm of the study could begin as early as December 2020 AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, has submitted a protocol amendment request to the U.S. Food and Drug Administration that would allow it to test immediate…

WednesdayNov 25, 2020 10:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) IND Application for Cancer Drug Berubicin Accepted for Review

CNS Pharmaceuticals wants to obtain FDA authorization for an Investigational New Drug application for drug candidate Berubicin, a novel treatment for Glioblastoma Multiforme Company believes it’s on track to start in Q1 2021 a potentially pivotal Phase II Berubicin trial with adult GBM patients who have failed their primary treatment for the disease Separately, a Phase II adult trial and a first-ever Phase I pediatric trial are slated to begin in 2021 in Poland in collaboration with sub-licensee partner, WPD Pharmaceuticals Members of CNS’s management team attended A.G.P.’s Virtual Health Symposium, meeting 1-on-1 with investors CNS Pharmaceuticals (NASDAQ: CNSP), a…

TuesdayNov 24, 2020 11:30 am

Researchers Design Wearable Sensors That Can Detect Employee Fatigue

Scientists have been designing devices that detect a worker’s alertness. The aim of this? To monitor for fatigue. Fatigue in a work setting can cause injuries or accidents and sometimes even loss of lives. Various industrial disasters, such as the Chernobyl nuclear accident, have been linked to worker fatigue. These wearable devices measures the breathing rate of their users as well as their muscle contractions, sweating and heart rate. The research, which was reported in this month’s issue of “IEEE Sensors Journal,” has a team of researchers from Italy explain how the innovative device works, adding that the individuals’ breathing…